Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- Long-term safety and efficacy of brivaracetam in adults with focal seizures Results from an open-label, multinational, follow-up trial No ClinicalTrials.gov identifier reported
- Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial No ClinicalTrials.gov identifier reported
- Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis No ClinicalTrials.gov identifier reported
- Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy No ClinicalTrials.gov identifier reported
- Long-term safety and efficacy of recombinant factor IX Fc fusion protein (rFIXFc) in previously treated subjects of all ages with haemophilia B: Final results from the B-YOND extension trial NCT01425723
- Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously treated children, adolescents, and adults with severe hemophilia A: Final results from ASPIRE NCT01454739
- Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously treated children, adolescents, and adults with severe hemophilia A: Final results from ASPIRE No ClinicalTrials.gov identifier reported
- Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A No ClinicalTrials.gov identifier reported
- Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE) NCT01454739
- Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to tumor necrosis factor inhibitors No ClinicalTrials.gov identifier reported
- Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis with 1 or >1 prior tumor necrosis factor inhibitor failures No ClinicalTrials.gov identifier reported
- Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment NCT01061736
- Long-term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia No ClinicalTrials.gov identifier reported
- Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With Shp607 in Extremely Premature Infants No ClinicalTrials.gov identifier reported
- Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis NCT02632175
- Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus No ClinicalTrials.gov identifier reported
- Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus NCT03920267
- Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX No ClinicalTrials.gov identifier reported
- Long-term safety and tolerability of TAK-881 in subjects with Primary Immunodeficiency Diseases (PIDD) No ClinicalTrials.gov identifier reported
- Long-Term Safety and Tolerability Study of Linerixibat for the Treatme No ClinicalTrials.gov identifier reported
- Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE) No ClinicalTrials.gov identifier reported
- Long-term, safety extension study of OLZ/SAM in pediatric subjects with schizophrenia or bipolar I disorder NCT04987229
- Long-term, safety extension study of OLZ/SAM in pediatric subjects with schizophrenia or bipolar I disorder (ENLIGHTEN Youth Extension) NCT04987229
- Long-term, safety extension study of OLZ/SAM in pediatric subjects withschizophrenia or bipolar I disorder (ENLIGHTEN Youth Extension) NCT05303064
- Long-term, safety extension study of OLZ/SAM in pediatric subjects withschizophrenia or bipolar I disorder (ENLIGHTEN Youth Extension) NCT04987229
- Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 No ClinicalTrials.gov identifier reported
- Long-term Safety in Paediatric Patients B-precursor ALL Treated with Blincyto or SOC then Transplant No ClinicalTrials.gov identifier reported
- Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies No ClinicalTrials.gov identifier reported
- Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies No ClinicalTrials.gov identifier reported
- Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies No ClinicalTrials.gov identifier reported
- Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies No ClinicalTrials.gov identifier reported
- Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No ClinicalTrials.gov identifier reported
- Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C NCT05028569
- Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C NCT04166058
- Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C NCT05771428
- Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C NCT04166058
- Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation No ClinicalTrials.gov identifier reported
- Long-Term Safety of Pirtobrutinib in Participants From Study Loxo-Btk-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Or Non-Hodgkin Lymphoma NCT06876662
- Long-Term Safety of Sarilumab in Rheumatoid Arthritis: An Integrated Analysis with up to 7 Years? Follow-Up NCT01146652
- Long Term Safety of Sativex Oromucosal Spray Sativex Nabiximols As Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain. No ClinicalTrials.gov identifier reported
- Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorderresults From the Open-Label Extension Periods of Sakurasky and Sakurastar No ClinicalTrials.gov identifier reported
- Long Term Safety Protocol for ACRYSOF CACHET Phakic Lens No ClinicalTrials.gov identifier reported
- Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder NCT04708834
- Long Term Safety Study of Amifampridine Phosphate in Patients With Musk Antibody Positive and Achr (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis No ClinicalTrials.gov identifier reported
- Long Term Safety Study of Amifampridine Phosphate in Patients With Musk Positive Antibody Positive Myasthenia Gravis Patients No ClinicalTrials.gov identifier reported
- Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women NCT03213457
- Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No ClinicalTrials.gov identifier reported
- Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women NCT05969223
- Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women NCT04499248
- Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women NCT05439616